Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia anomala extract is a botanical extract derived from the herb Artemisia anomala S. Moore, traditionally used in Chinese medicine for the treatment of inflammatory diseases such as enteritis, atopic dermatitis, chronic bronchitis, rheumatism, and hepatitis. Key mechanisms involve inhibition of inflammatory mediators, including downregulation of inducible nitric oxide synthase (iNOS), suppression of pro-inflammatory cytokines (such as IL-1β and IL-6), and inhibition of the nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways. The extract, especially its ethyl acetate and ethanol fractions, shows pronounced anti-inflammatory and antioxidative activities in vitro and in vivo, potentially making it useful as a functional food ingredient or anti-inflammatory agent. Although widely used in traditional medicine, its efficacy and safety for clinical indications remain to be established through rigorous human trials[3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia anomala extract.